The use of antibodies as a means of targeting therapeutic agents has undergone renewed emphasis in recent times following the introduction of hybridoma techniques for preparing monoclonal antibodies (K6hler & Milstein, 1975) . Several groups have shown that anti-tumour antibodies can be used to direct toxins or therapeutic drugs to appropriate tumour cells and thereby achieve increased cytotoxicity (Ghose & Blair, 1978;  Thorpe & Ross, 1982) . We have previously reported the selective action in vitro of conjugates of vindesine or methotrexate (MTX) with a monoclonal antibody to a human osteogenic sarcoma cell line, against target cells which express the relevant antigen (Embleton et al., 1983; Garnett et al., 1983) .
The successful use of such conjugates depends on a number of transport-related factors such as the ability of the conjugate to localise and persist at the tumour site, and its intratumour and intracellular penetration. The behaviour of the tumour cells themselves in response to the conjugate will also determine its overall therapeutic efficacy. In conventional cancer chemotherapy the development of resistance to drugs, such as MTX, is a common problem (Harrap et al., 1971) and this is equally possible in the case of drug-antibody conjugates. In addition, there is the possibility that tumour cells might lose antigen expression, either by selection of non-antigenic clones or by antibody-induced modulation, and consequently fail to bind sufficient conjugate to achieve cytotoxicity.
It is highly unlikely that a single dose of a drugantibody conjugate would deplete the host of all tumour cells in in vivo therapy, mainly because of limited access to the whole cell population. It is therefore likely that some cells will survive the initial treatment, and it is of interest to determine to what extent they may be modified in terms of factors influencing their subsequent susceptibility. We have investigated this problem using an in vitro model in which cells of a human osteogenic sarcoma line (791T) were treated with a conjugate of methotrexate (MTX) linked to an anti-osteogenic sarcoma antibody (79IT/36) by a human serum albumin bridge (Garnett et al., 1983) .
Materials and methods

Tumour cells
The human osteogenic sarcoma line HS-791T (791T) was maintained as a monolayer cell line in 90mm plastic culture dishes (Sterilin, Teddington, U.K.) in Eagles Minimum Essential Medium supplemented with 10% newborn calf serum (growth medium), and routinely passaged by harvesting with a mixture of 0.25% trypsin and 0.5% EDTA in Hanks' balanced salt solution (HBSS). Clones derived from this cell line were grown and passaged in an identical manner.
Conjugate
The conjugate consisted of methotrexate linked via human serum albumin to anti-osteogenic sarcoma antibody 791T/36 (Embleton et al., 1981) as previously described (Garnett et al., 1983 ). It will be referred to as MXT-HSA-791T/36 conjugate. Previous studies have established that it is cytotoxic for 791T and other tumour cells expressing the 791T/36-defined antigen, but not for cells which do not express the antigen (Garnett et al., 1983) . It was stored in PBS (pH7.2) at 4°C, under which conditions it was stable for more than 12 months.
Isolation of clones surviving treatment with conjugate 791T cells (103) were plated in 60mm culture dishes in 4 ml of growth medium, either untreated or containing MTX-HSA-791T/36 conjugate at MTX concentrations of 50 ng ml -1 or 100 ng ml -1. These concentrations were chosen because they had previously resulted in between 99% and 100% inhibition of 791T colony growth (Garnett et al., 1983) . The dishes were incubated for 10 days at 37°C, and were examined microscopically for 791T
colonies. The few colonies observed in MTX-HSA-791T/36 treated dishes were isolated in greased glass cloning cylinders and trypsinised from the dishes (Puck et al., 1956 Colony inhibition assay Toxicity of free MTX (Lederle Laboratories, Gosport, U.K.) or MTX-HSA-791T/36 for 791T cells and 791T/MH7R clones was tested by a colony inhibition assay. Two hundred cells were plated in 1 ml of growth medium in 35mm culture dishes and incubated for 4 h at 37°C to allow attachment. Using quadruplicate dishes 1 ml of growth medium was added, containing various dilutions of MTX or conjugate (at equivalent MTX concentrations) as appropriate. In each case controls were included which contained added growth medium only. The dishes were incubated 5-6 days at 37°C. They were then rinsed with 0.9% w/v NaCl and the cell colonies were fixed with methanol and stained with 0.1% aqueous crystal violet solution. Colonies were counted under x40 stereoscopic magnification and the results were expressed, for each cell line, as percentage colony growth relative to that in controls, i.e. The expression of monoclonal antibody 791T/36-defined antigen on 791T/MH7R clones was analysed by flow cytofluorometry using affinitypurified 791T/36 conjugated to fluorescein isothiocyanate (FITC) (Price et al., 1983) . The antigen recognised by this antibody is a membraneassociated monomeric glycoprotein of apparent molecular weight 72,000 (Price et al., 1983) . Cells (2 x 10) were incubated for 30 min at 4°C with tenfold dilutions of FITC-791T/36 in 1 ml of PBS or HBSS, ranging from 20 jug ml-1 to 2ng ml-1 antibody protein. Growth of clones in immune-deprived mice Female mice (Bantin and Kingman, Hull, U.K.) were thymectomised at 3-4 weeks of age and up to 20 weeks later were given cytosine arabinoside (200mg kg-1). After two days the mice were subjected to 9 Gy whole-body y-irradiation and were used as recipients of xenografts within 2 weeks. Inocula of 106 cultured 791T or 791T/MH7R cells were injected subcutaneously in the right flank and the mice were maintained for 2 months to observe the growth of xenografts.
Results
Isolation of clones following MTX-HSA-79JT/36 treatment Treatment with MTX-HSA-791T/36 conjugate at doses of 50ngml-1 and lOOngml-1 markedly inhibited growth of 791T cells as reported previously (Garnett et al., 1983) . Table I Colony inhibition tests Colony inhibition tests were performed initially to determine whether 791T/MH7R clones were resistant to MTX compared with 791T parental cells. Plated cells were exposed continuously to various concentrations of MTX and after 5 days the colonies were enumerated and compared with numbers in untreated controls (Table III) . MTX completely inhibited the growth of 791T cells at 100 ngmlP-, and the IC50 was 9 ngml-1 in repeated experiments. Three of the four 791T/MH7R clones showed almost identical sensitivity to MTX, but 791T/MH7R/5 was more resistant in the 10-30 ng ml-1 range, resulting in an IC50 of 17 ngml-1.
Considering the persistence of 791T/36-defined antigen and the essentially normal sensitivity to MTX, it could be predicted that 791T/MH7R clones should be susceptible to a further exposure to MTX-HSA-791T/36 conjugate. This was tested (Table IV) and in all cases the clones were inhibited by the conjugate. (Clone 791T/MH7R/4 appeared slightly more sensitive to low doses, and clones 791T/MH7R/12 and 791T/MH7R/14 were slightly more resistant to high doses than the parental 791T 'IC50 =Concentration of MTX producing 50% inhibition of colony formation. 791T (Garnett et al., 1983) . These studies had also indicated that a small number of 791T clones might survive an initial exposure to the conjugate, and it was of interest to examine these for growth properties, antigenicity and drug susceptibility. It is apparent from the present investigation that clones which initially survive conjugate treatment fall into two categories, the majority subsequently failing to proliferate indefinitely and the minority growing at a similar rate to parental cells both in vivo and in vitro. Only the latter clones became available in numbers great enough for more detailed analysis. The proliferating conjugate-treated (791T/MH7R) clones showed no loss of 791T/36-defined antigen as detected by flow cytofluorometry, based on the range of antigenicity of uncloned 791T or normal 791T clones. On the contrary, two 791T/MH7R clones showed enhanced antigenicity for which there was no obvious explanation nor any correlation with other parameters. For example, 791T/MH7R/12, with an antigen density 6 times higher than the normal mean, showed no increased susceptibility to conjugate. Flow cytofluorometric studies have indicated that the 791T/36-defined antigen is present on all 791T cells, either cultured or obtained by dissociation of xenografts (Price et al., 1983 ; R.A. Robins, unpublished findings) but it could be postulated that non-antigenic clones might exist below the limits of detection. However, this is evidently not the explanation for escape from the MTX-HSA-791T/36 conjugate. The relative antigenic homogeneity characteristic of 791T is a feature not likely to be shared by hwnan tumours experienced clinically, but this problem might be overcome by using "cocktails" of antibodies with different specificities, as is the current practice in removal of neoplastic cells from bone marrow aspirates (Treleaven et al., 1984) . The emergence of "non-antigenic" clones might thus also be a rare event in clinical practice.
The 791T/MH7R clones were sensitive to MTX in the form of free drug, and subsequent tests confirmed the prediction that they would be as sensitive to the cytotoxic effect of MTX-HSA-791T/36 conjugate as the untreated 791T parental line. There were minor differences in colony formation at particular concentrations of conjugate, but the IC50 values for parental cells and clones fell in the narrow range of 1.5 to 3.0ngm1-1 expressed in terms of MTX content. Extrapolated to the in vivo situation, these extremes are unlikely to be of practical significance in therapy. It is possible that these clones arose from cells which temporarily became drug-insensitive during the initial exposure but regained their susceptibility during subsequent clonal expansion, or that the threshold of effectiveness of MTX was not reached in the initial exposure.
The overall conclusion from these experiments is that cells escaping the effects of a cytotoxic drugmonoclonal antibody conjugate do not necessarily constitute truly resistant clones, but may be either incapable of further progressive growth (i.e. only short-term survivors) or long-term survivors susceptible to a further treatment with the same conjugate. This supports the design of protocols for in vivo therapy employing multiple doses of conjugate spread over an extended time period.
